Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Top Page
Fresenius SE & Co
(OTC:FSNUY)
59Neutral
Fresenius SE & Co (FSNUY) vs. S&P 500 (SPY)
Market Cap
$25.03B
Dividend YieldN/A
Average Volume (3M)2.63K
Price to Earnings (P/E)49.1
Beta (1Y)0.22
Revenue Growth-30.23%
EPS GrowthN/A
CountryUS
Employees176,486
SectorHealthcare
Sector Strength64
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.23
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume2,626
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.55
Price to Cash Flow (P/CF)3.10
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.50Price Target Upside1.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Fresenius SE & Co Business Overview & Revenue Model
Company DescriptionFresenius SE & Co. KGaA is a global healthcare group based in Germany, operating in the healthcare and pharmaceutical sectors. The company is structured into several business segments, including Fresenius Medical Care, Fresenius Helios, Fresenius Kabi, and Fresenius Vamed. These segments specialize in providing kidney dialysis services and products, hospital management, infusion therapies, clinical nutrition, and healthcare facility management, respectively. Fresenius serves a diverse range of healthcare needs, delivering products and services aimed at improving patient care worldwide.
How the Company Makes MoneyFresenius SE & Co. generates revenue through multiple streams across its business segments. Fresenius Medical Care, the largest segment, earns income primarily by providing dialysis care and selling dialysis products such as machines and related consumables to healthcare providers. Fresenius Helios operates hospitals, earning revenue from patient care services, while Fresenius Kabi generates income through the sale of pharmaceuticals and medical devices, focusing on infusion therapies and clinical nutrition. Fresenius Vamed contributes by managing healthcare facilities and providing technical services. The company's revenue is supported by a combination of direct patient services, product sales, and healthcare infrastructure management, with strategic partnerships and acquisitions enhancing its market presence and financial performance.
Fresenius SE & Co Financial Statement Overview
Summary
Fresenius SE & Co exhibits reasonable operational efficiency with strong cash flow metrics but faces challenges with declining revenue and negative profitability. The balance sheet remains robust with manageable leverage. While cash flows are favorable, sustaining profitability is crucial for improving overall financial health.Income Statement
The company shows declining revenue from the previous year, indicating potential challenges in maintaining sales momentum. Gross profit margin stands at 23.81% TTM, highlighting reasonable cost management, but the net profit margin is negative due to recent losses. EBITDA margin is healthy at 13.02%, showing operational efficiency. However, the negative net income raises concerns about profitability sustainability.55
Neutral
Balance Sheet
The debt-to-equity ratio is 0.71, indicating a balanced leverage position. Return on Equity is negative due to current losses, which is concerning. The equity ratio of 44.45% TTM suggests a strong equity base. Overall, the balance sheet shows stability but is affected by profitability concerns.60
Neutral
Cash Flow
Free cash flow is positive and the free cash flow to net income ratio is strong due to negative net income, indicating cash flow resilience despite profitability issues. Operating cash flow to net income ratio is positive, showcasing efficient cash generation capabilities. However, declining free cash flow growth is a potential area of concern.70
Positive
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 22.21B | 22.30B | 40.84B | 37.52B | 36.28B | 35.41B | Gross Profit |
| 5.29B | 5.06B | 10.72B | 10.31B | 10.32B | 10.35B | EBIT |
| 1.40B | 1.14B | 3.51B | 4.16B | 4.38B | 4.63B | EBITDA |
| 2.89B | 2.73B | 3.10B | 6.95B | 7.19B | 7.25B | Net Income Common Stockholders |
| -383.00M | -594.00M | 2.12B | 2.82B | 2.82B | 3.03B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.29B | 2.56B | 2.35B | 2.75B | 2.00B | 1.79B | Total Assets |
| 45.28B | 45.28B | 76.42B | 71.96B | 66.65B | 67.01B | Total Debt |
| 15.83B | 15.83B | 27.76B | 27.16B | 25.91B | 27.26B | Net Debt |
| 13.54B | 13.54B | 25.59B | 24.55B | 24.08B | 25.60B | Total Liabilities |
| 25.63B | 25.63B | 44.20B | 42.67B | 40.62B | 40.43B | Stockholders Equity |
| 19.00B | 19.00B | 20.41B | 19.00B | 16.95B | 16.78B |
| Cash Flow | Free Cash Flow | ||||
| 2.44B | 3.32B | 2.28B | 3.03B | 4.14B | 1.80B | Operating Cash Flow |
| 3.29B | 4.46B | 4.20B | 5.08B | 6.55B | 4.26B | Investing Cash Flow |
| -2.08B | -3.19B | -2.61B | -2.82B | -3.01B | -4.86B | Financing Cash Flow |
| -2.33B | -1.38B | -1.60B | -1.45B | -3.12B | -484.00M |
Fresenius SE & Co Technical Analysis
Positive
11.33
Price Trends
10.50
Positive
9.81
Positive
9.37
Positive
Market Momentum
0.22
Negative
60.41
Neutral
94.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 11.33 is above the 20-day moving average (MA) of 10.74, above the 50-day MA of 10.50, and above the 200-day MA of 9.37, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 60.41 is Neutral, neither overbought nor oversold. The STOCH value of 94.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $11.78B | 3.84 | 110.75% | ― | 0.57% | 440.71% | |
73 Outperform | $11.43B | 10.43 | 17.82% | 0.48% | 10.82% | 65.64% | |
69 Neutral | $14.01B | 24.20 | 3.87% | 1.88% | -0.57% | 8.25% | |
67 Neutral | $10.00B | 22.20 | 24.52% | 0.65% | 11.91% | 28.47% | |
64 Neutral | $10.80B | 12.93 | 159.08% | ― | 5.56% | 45.02% | |
59 Neutral | $25.03B | 49.07 | 5.47% | ― | -30.23% | ― | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% |
* Healthcare Sector Average
Performance Comparison
FSNUY
Fresenius SE & Co
11.33
4.05
55.63%
DVA
DaVita
139.56
6.79
5.11%
FMS
Fresenius Medical Care
24.17
4.35
21.95%
EHC
Encompass Health
101.41
19.26
23.44%
THC
Tenet Healthcare
124.24
26.73
27.41%
UHS
Universal Health
174.00
9.56
5.81%
Fresenius SE & Co Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: 18.02% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance, strategic restructuring, and resumed dividend payments, indicating overall progress. However, challenges in China, the end of energy relief payments, and competitive pressures in Biopharma create headwinds.Highlights
Strong Financial Performance in 2024
Fresenius achieved high single-digit organic revenue growth, with EBIT growing even faster in double digits. Key growth drivers included MedTech, Nutrition, and Biopharma, with Biopharma showing 76% year-over-year growth.
Significant Margin and Cash Flow Improvement
The company improved its EBIT margins by 180 basis points over the past two years and achieved a strong EPS growth of 14% in 2024, compared to a 13% decline in 2022. Operating cash flow neared €1 billion in the fourth quarter.
Successful Portfolio Restructuring
Fresenius successfully concluded several strategic measures, including divesting non-core assets, deconsolidating Fresenius Medical Care, and exiting Vamed, resulting in a simpler and more focused company.
Resumption of Dividend Payments
Fresenius announced a proposed dividend of €1 per share for 2024, reflecting financial strength and a commitment to shareholder value.
Lowlights
Challenges in China
Fresenius faces challenges due to the national volume-based procurement (NVBP) program in China, which affects the performance of key products like keto. The company does not anticipate a substantive change to the operating environment in the short term.
Impact of Energy Relief Payment Ending
Helios Germany faces a tough year-on-year comparison due to the absence of a €140 million energy relief payment received in 2023, creating headwinds for 2025.
Regulatory and Market Challenges for Biopharma
Biopharma faces competitive market dynamics and regulatory approval processes, impacting the timing and scale of product launches like ustekinumab and denosumab.
Company Guidance
During the call, Fresenius provided a comprehensive outlook for 2025, emphasizing continued momentum in financial and operational performance. The guidance for the fiscal year 2025 includes organic revenue growth of 4% to 6% and EBIT growth of 3% to 7%, both at constant currency. The company highlighted significant achievements in 2024, including surpassing €470 million in structural cost improvements and achieving high single-digit organic revenue growth, with EBIT expanding even faster in double digits. Key growth drivers were the MedTech, Nutrition, and Biopharma segments, with Biopharma particularly standing out with 76% year-over-year growth. The company also noted Helios' consistent revenue performance and a substantial improvement in EPS, moving from a 13% decline in 2022 to 14% growth in 2024. The guidance reflects a confident outlook, with a focus on executing its "Rejuvenate" strategy and achieving further operational efficiencies and market expansion.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.